oral semaglutide approval FDA approves first-ever GLP-1RA for obesity and chronic weight management. Meet Wegovy (semaglutide) tablets. https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-wegovy-pill-the-first-and-only- oral-glp-1-for-weight-loss-in-adults FDA Approves Oral Semaglutide: First

10.3390/nu2030355 35 CaldernF.Chauveau-DuriotB.PradelP.MartinB.GrauletB.DoreauM.et al

They further note that, given peripherally, BPC 157 counteracts central dopamine-system disturbances and induces serotonin release in the substantia nigra, and that it can heal various wounds and instantly recover disturbed lower esophageal and pyloric sphincter pressure in rats with long-standing esophagitis

Circulation 131(10):871881 Buller S, Blouet C (2024) Brain access of incretins and incretin receptor agonists to their central targets relevant for appetite suppression and weight loss

Vitamin C (L-ascorbic acid) destabilizes copper peptides

Humans express three genes in the LPIN family, LPIN1, LPIN2, and LPIN3

In Studies 2 (NCT#03548935), 3 (NCT#03552757), and 4 (NCT#03611582), WEGOVY or matching placebo was escalated to 2.4 mg subcutaneous injection weekly during a 16-week period followed by 52 weeks on maintenance dose